JOONEM

Joonem is an early-stage biotechnology company dedicated to advancing the field of longevity and regenerative medicine through cellular reprogramming. The company focuses on developing therapies that target the underlying biological drivers of aging, aiming to restore youthful function to tissues and organs. By leveraging proprietary epigenetic technologies, Joonem seeks to reverse age-related cellular decline and treat a variety of chronic conditions, including metabolic and neurodegenerative diseases. Their approach combines cutting-edge research in sirtuin activation and metabolic signaling to extend healthy human lifespan. Joonem is currently in the pre-clinical phase, working to validate its therapeutic candidates for future clinical trials.